Pyxis Oncology (PYXS) Profit After Tax (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Profit After Tax of -$18.0 million for Q4 2025, up 49.75% year-over-year from -$12.0 million in Q4 2024, and up 17.89% quarter-over-quarter from -$21.9 million in Q3 2025.
Pyxis Oncology (PYXS) Profit After Tax (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Profit After Tax for 6 consecutive years, with -$18.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax rose 49.75% year-over-year to -$18.0 million; the TTM figure through Dec 2025 stood at -$79.4 million (down 3.0% YoY), while the FY2025 annual figure was -$79.6 million, down 3.0% from the prior year.
- Profit After Tax rose to -$18.0 million in Q4 2025 per PYXS's latest filing, from -$21.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$3.3 million in Q1 2024 and bottomed at -$36.8 million in Q1 2021.
- Historically, Profit After Tax has averaged -$21.4 million across 5 years, with a median of -$20.0 million in 2023.
- Annual changes were most pronounced in 2024 — Profit After Tax soared 83.08% — and 2025, when it slumped 549.82%.
- Pyxis Oncology's Profit After Tax stood at -$16.9 million in 2021, then slumped by 114.1% to -$36.1 million in 2022, then jumped by 56.95% to -$15.5 million in 2023, then tumbled by 130.64% to -$35.8 million in 2024, then surged by 49.75% to -$18.0 million in 2025.
- Business Quant data shows PYXS's Profit After Tax at -$18.0 million in Q4 2025, -$21.9 million in Q3 2025, and -$18.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | -25.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.35 Mn |
| Dec 31, 2025 | -18.01 Mn |
| Sep 30, 2025 | -21.93 Mn |
| Jun 30, 2025 | -18.35 Mn |
| Mar 31, 2025 | -21.16 Mn |
| Dec 31, 2024 | -35.83 Mn |
| Sep 30, 2024 | -20.75 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -15.53 Mn |
| Sep 30, 2023 | -23.05 Mn |
| Jun 30, 2023 | -16.68 Mn |
| Mar 31, 2023 | -19.24 Mn |
| Dec 31, 2022 | -36.08 Mn |
| Sep 30, 2022 | -27.67 Mn |
| Jun 30, 2022 | -25.56 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -16.85 Mn |
| Sep 30, 2021 | -14.18 Mn |
| Jun 30, 2021 | -8.15 Mn |